Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

NICE Issues Second Draft “No” on ixazomib

Posted on: 06 Sep 17

The National Institute for Health and Care Excellence (NICE) has issued a second draft “no” on ixazomib (Ninlaro®) for the treatment of patients with relapsed or refractory myeloma.

This means that a final decision on the treatment has not been made but that, as it stands, NICE is not minded to recommend ixazomib be made routinely available on the NHS in England and Wales.  

The NICE decision was for the treatment combination of ixazomib, lenalidomide (Revlimid®) and dexamethasone. This decision will not affect patients already being treated with ixazomib, either through the Named Patient Programme (NPP) or on a clinical trial.

Myeloma UK Acting Policy and Public Affairs Manager, Shelagh McKinlay said: “This second draft “no” is disappointing, but while the consultation is ongoing there is still the potential for a positive decision to be reached. We are glad that NICE have decided to seek further views before reaching a final decision.

“Triple combination treatments such as this one are becoming the international standard in myeloma treatment and patients in the UK deserve to have access to them. Ixazomib is not only an effective treatment option, it is the first oral treatment of its kind, offering patients much needed flexibility in how they live their lives.

“The company have requested that the treatment be considered for funding through the new Cancer Drugs Fund (CDF). The CDF is still relatively new and it is important that it reaches its full potential to deliver faster access to the most promising new treatments. We will continue to work with the company and NICE to try to deliver a positive outcome for patients.”

Editor's Details

Mike Wood

Last updated on: 06/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.